mass spectrometry profiling for the detection of bacteria has become one of the diagnostic methods of choice during the last the years, replacing conventional but more expensive biochemical methods for identification of bacterial (sub-) species [12] . In a review, Markus Kostrzewa and co-workers (contribution in this issue, pp. 767-778) discuss the additional application of MALDI-TOF MS for detecting (antibiotic) resistance, a challenging daily problem in the hospital. Furthermore, Harald Mischak and colleagues (contribution in this issue, pp. 779-793) explain in a review the usefulness of capillary electrophoresis coupled to mass spectrometry for analysing complex biological material by making use of several protein markers and detecting efficiently diseases such as bladder cancer.
In addition to these various papers, three research articles concretely show the potential impact of using proteomics-based approaches for clinical application. Ute Ceglarek, Joachim Thiery and co-workers (contribution in this issue, pp. 794-801) developed a standardised sample pre-treatment protocol for absolute quantification of apolipoproteins in human serum using LC-MS/MS detection. The protocol shall allow the potential user to perform facile analysis of apolipoproteins in the context of cardiovascular diseases. Moreover, Jörg Hoheisel and colleagues (contribution in this issue, pp. 802-812) use high-content antibody microarrays for the analysis of plasma of patients with different B-cell lymphomas to identify classifiers, which can subsequently be useful as starting points for further validation as diagnostic markers. Finally, Thorsten Cramer, Joachim Klose and co-workers (contribution in this issue, pp. 813-824) present a study exemplifying the application of two dimensional gels for protein quantification combined with mass spectrometry based protein identification to functionally analyse emerging resistance due to targeted cancer treatment. Such studies may contribute to improve our understanding on the unwanted dramatic relapse of cancer therapies.
We hope that the various articles will give the reader a flavour on the potential of proteomics methodologies for clinical application-and in the best case inspire the reader to develop new ideas for eventually better diagnosing and treating the patient!
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